Cortex Pharmaceuticals Inc.
The Irvine drug development company’s losses in the fiscal first quarter ended Sept. 30 widened to $1.2 million, or 16 cents a share, from $954,610, or 16 cents a share, a year ago. No revenue was reported.
The Irvine drug development company’s losses in the fiscal first quarter ended Sept. 30 widened to $1.2 million, or 16 cents a share, from $954,610, or 16 cents a share, a year ago. No revenue was reported.
